I don't think he's expecting news but rather expressing disappointment with news over the last year. We haven't heard anything particularly compelling in a very long time, and what we have heard has been rehashed entirely or minimally expanded over an extended period of time on a few occasions.
We're instead greeted with new excuses to burn cash on new R&D such as DUAL, biomarkers, etc., instead of dialing back the existing burn rate aside from suspension of HER2 which was already the least expensive franchise aside from NEO which hasn't ramped up, per 10-Qs. The money invested into HER2 is now sitting there, collecting dust and hoping to be sold off to at least recoup the costs. To me this suspension/restructuring signals that, on top of everything else, even their ability to spend money wisely and efficiently on R&D isn't/hasn't been up to par.
I would have preferred they reduced Personnel Expenses by 10% (~500K/quarter) and keep HER2 (~500K/quarter) running, even if just for appearances while selling it off. It looks less desperate and may have convinced any interested parties that it commands a higher price tag than it does now.
It really looks to me like they're buying time and drawing this out, and it isn't becoming. I wish it wasn't this way, but I'll call a spade a spade and see no reason to sugarcoat it. I really hope I'm wrong and there's a surprise in store somewhere, but they haven't given much to be confident about.
News 
Market Data 
Discover 
AI
